Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer
Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer
复制标题
DOI：
10.1007/s13139-012-0142-z
复制
发表时间：
2012-09-01
影响因子：
1.3
通讯作者：
Kang, Won Jun
中科院分区：
文献类型：
--
作者：
Choi, Yun-Jung;Cho, Byoung Chul;Kang, Won Jun
目的表皮生长因子受体（EGFR）基因突变是非小细胞肺癌（NSCLC）治疗和预后的潜在靶点。我们评估了氟脱氧葡萄糖（FDG）摄取和EGFR突变之间的相关性，以及它们的预后implications.Methods共163例经病理证实的NSCLC患者入选（99名男性和64名女性，中位年龄60岁）。所有患者在治疗前均接受FDG正电子发射断层扫描，并进行EGFR突变的遗传学研究。测量原发性肺癌的最大标准化摄取值（SUVmax），并相对于肝脏摄取进行标准化。比较野生型和EGFR突变体组之间的SUVmax。结果57例（60.8%）患者存在EGFR突变，其中57例（60.8%）患者存在EGFR突变。野生型肿瘤的SUVmax往往高于突变型肿瘤，但无显著差异（11.1 +/- 5.7 vs. 9.8 +/- 4.4，P=0.103）。19号外显子突变患者的SUVmax显著低于21号外显子突变或野生型患者（分别为P=0.003和0.009）。与野生型肿瘤相比，EGFR突变显示出延长的总生存期（OS）（P=0.004）。根据SUVmax，生存率无显著差异。19号外显子突变患者的OS和无进展生存期均显著长于野生型tumors.Conclusion在NSCLC患者中，19号外显子突变与较低的SUVmax相关，是良好生存的可靠预测因子。
Purpose Mutations in the epidermal growth factor receptor (EGFR) gene have been identified as potential targets for the treatment and prognostic factors for non-small cell lung cancer (NSCLC). We assessed the correlation between fluorodeoxyglucose (FDG) uptake and EGFR mutations, as well as their prognostic implications.Methods A total of 163 patients with pathologically confirmed NSCLC were enrolled (99 males and 64 females; median age, 60 years). All patients underwent FDG positron emission tomography before treatment, and genetic studies of EGFR mutations were performed. The maximum standardized uptake value (SUVmax) of the primary lung cancer was measured and normalized with regard to liver uptake. The SUVmax between the wild-type and EGFR mutant groups was compared. Survival was evaluated according to SUVmax and EGFR mutation status.Results EGFR mutations were found in 57 patients (60.8 %). The SUVmax tended to be higher in wild-type than mutant tumors, but was not significantly different (11.1 +/- 5.7 vs. 9.8 +/- 4.4, P=0.103). The SUVmax was significantly lower in patients with an exon 19 mutation than in those with either an exon 21 mutation or wild type (P=0.003 and 0.009, respectively). The EGFR mutation showed prolonged overall survival (OS) compared to wild-type tumors (P=0.004). There was no significant difference in survival according to SUVmax. Both OS and progression-free survival of patients with a mutation in exon 19 were significant longer than in patients with wild-type tumors.Conclusion In patients with NSCLC, a mutation in exon 19 was associated with a lower SUVmax and is a reliable predictor for good survival.